Expert Review of Anti-infective Therapy最新文献

Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis. 依拉维辛（ERV）治疗革兰氏阴性病原体感染的有效性和安全性：系统综述和荟萃分析。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-11 DOI: 10.1080/14787210.2024.2397663

Zehua Chen,Weijia Sun,Yulong Chi,Beibei Liang,Yun Cai

{"title":"Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis.","authors":"Zehua Chen,Weijia Sun,Yulong Chi,Beibei Liang,Yun Cai","doi":"10.1080/14787210.2024.2397663","DOIUrl":"https://doi.org/10.1080/14787210.2024.2397663","url":null,"abstract":"BACKGROUNDEravacycline (ERV) is a novel synthetic fluorocycline antibiotic with broad-spectrum antibacterial efficacy against pathogens. This study sought to investigate ERV's effectiveness and safety in treating Gram-negative pathogens (GNPs) infections.METHODSWe conducted a comprehensive search of PubMed, Cochrane Library, Embase, Web of Science, and ClinicalTrials.gov up to September 2023. Included in the review were studies assessing the efficacy or safety of ERV in treating GNP infections.RESULTSThree randomized controlled trials, seven cohort studies, and two case reports were included. There was no statistically significant difference between ERV and comparators in clinical cure (OR = 0.84, 95% CI = 0.59-1.19), microbiologic eradication (OR = 0.69, 95% CI = 0.36-1.33), and mortality (OR = 1.66, 95% CI = 0.81-3.41). However, a significantly higher rate of adverse events with ERV was observed compared to the control group (OR = 1.55, 95% CI = 1.21-1.99). Additionally, cohort studies reported a clinical cure rate of 73.2% (88.8% in RCTs), an AE rate of 4.5% (38.3% in RCTs), and mortality of 16.2% (1.5% in RCTs). Patients in RCTs received ERV monotherapy, whereas almost half of the patients in cohort studies were treated with ERV in combination with other antibiotics.CONCLUSIONSFurther studies are warranted to investigate the safety and efficacy of ERV monotherapy or combination therapy in critically ill patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142187808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating diagnostic tools, outcome measures and antibiotic approach in diabetic foot osteomyelitis: a scoping review and narrative synthesis. 评估糖尿病足骨髓炎的诊断工具、结果测量和抗生素治疗方法：范围界定综述和叙述性综述。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-10 DOI: 10.1080/14787210.2024.2403145

Satwik Motaganahalli,Gemma Reynolds,Suresh Haikerwal,Toby Richards,Trisha N Peel,Jason A Trubiano

引用次数: 0

MazEF Toxin-Antitoxin systems: their role in Mycobacterium tuberculosis stress response and drug resistance. MazEF 毒素-抗毒素系统：它们在结核分枝杆菌应激反应和抗药性中的作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-09 DOI: 10.1080/14787210.2024.2403021

Zoozeal Thakur, Renu Chaudhary, Promod K Mehta

引用次数: 0

Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex. 舒巴坦-杜鲁巴坦用于治疗鲍曼不动杆菌-醋酸钙复合菌。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-08 DOI: 10.1080/14787210.2024.2400703

Jordan R Covvey, Anthony J Guarascio

{"title":"Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex.","authors":"Jordan R Covvey, Anthony J Guarascio","doi":"10.1080/14787210.2024.2400703","DOIUrl":"10.1080/14787210.2024.2400703","url":null,"abstract":"Introduction: Infections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.Areas covered: This review provides a comprehensive discussion of sulbactam/durlobactam, including basic characteristics, in vitro activity, and clinical trial data supporting its use for the treatment of ABC. Manufacturer's data, published literature to date, and conference data are utilized in this review.Expert opinion: Sulbactam/durlobactam offers clinicians a new and effective treatment option for resistant ABC infection. Sulbactam, when combined with durlobactam, displays enhanced potency against ABC isolates, which has translated into positive clinical outcomes observed in clinical trials and post-marketing case studies. Although overall treatment indications and clinical experience are limited to date, sulbactam/durlobactam offers a familiar and favorable safety profile in comparison with alternative agents. Factors associated with use of combination antibiotic therapy, availability of commercial drug susceptibility testing, and cost-effectiveness are all currently key considerations for sulbactam/durlobactam use.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alternative drugs for the treatment of gonococcal infections: old and new. 治疗淋球菌感染的替代药物：新旧药物。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-06 DOI: 10.1080/14787210.2024.2401560

Susannah Franco, Margaret R Hammerschlag

{"title":"Alternative drugs for the treatment of gonococcal infections: old and new.","authors":"Susannah Franco, Margaret R Hammerschlag","doi":"10.1080/14787210.2024.2401560","DOIUrl":"https://doi.org/10.1080/14787210.2024.2401560","url":null,"abstract":"Introduction: The rise in antibiotic resistance to N. gonorrhoeae poses a substantial threat to effective gonorrhea treatment. Historical progression of resistance from sulfonamides to the more recent declines in efficacy of fluoroquinolones and susceptibilities of ceftriaxone highlight the urgent need for novel therapeutic approaches, necessitating the examination of alternative and new antibiotics.Areas covered: This review examines the potential of repurposing older antibiotics for gonorrhea treatment, with a focus on their efficacy and limitations. These include aztreonam, ertapemen, and fosfomycin. New oral drugs zoliflodacin and gepotidacin are in late clinical development, but there are concerns regarding their effectiveness for extragenital infections and the development of resistance.Expert opinion: While ceftriaxone remains the best treatment for gonorrhea across all anatomic sites, resistance may eventually limit its use. Among older antibiotics, ertapenem shows the most potential as an alternative but shares the same administration drawbacks as ceftriaxone. New oral drugs zoliflodacin and gepotidacin initially appeared promising, but their efficacy for pharyngeal infections and potential for resistance development are concerning. Phase 3 trial results have not been made available except through press releases, which perpetuates concerns. Understanding pharmacokinetic and pharmacodynamic profiles of antibiotics will be key in optimizing future treatment recommendations.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of resistant and refractory cytomegalovirus infections after transplantation. 移植后耐药和难治性巨细胞病毒感染的管理。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-05 DOI: 10.1080/14787210.2024.2399647

Justin H Pham, Raymund R Razonable

{"title":"Management of resistant and refractory cytomegalovirus infections after transplantation.","authors":"Justin H Pham, Raymund R Razonable","doi":"10.1080/14787210.2024.2399647","DOIUrl":"10.1080/14787210.2024.2399647","url":null,"abstract":"Introduction: Cytomegalovirus (CMV) is a classic opportunistic infection in transplant recipients. Treatment-refractory CMV infections are of concern, with growing identification of strains that have developed genetic mutations which confer resistance to standard antiviral therapy. Resistant and refractory CMV infections are associated with worse patient outcomes, prolonged hospitalization, and increased healthcare costs.Areas covered: This article provides a comprehensive practical overview of resistant and refractory CMV infections in transplant recipients. We review the updated definitions for these infections, antiviral pharmacology, mechanisms of drug resistance, diagnostic workup, management strategies, and host-related factors including immune optimization.Expert opinion: Resistant and refractory CMV infections are a significant contributor to post-transplant morbidity and mortality. This is likely the result of a combination of prolonged antiviral exposure and active viral replication in the setting of intensive pharmacologic immunosuppression. Successful control of resistant and refractory infections in transplant recipients requires a combination of immunomodulatory optimization and appropriate antiviral drug choice with sufficient treatment duration.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammatory response to sars-CoV 2 and other respiratory viruses. sars-CoV 2 和其他呼吸道病毒的炎症反应。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-04 DOI: 10.1080/14787210.2024.2400548

André Emilio Viñán Garcés, Eder Cáceres, Juan Olivella Gómez, Ignacio Martín-Loeches, Luis Felipe Reyes

{"title":"Inflammatory response to sars-CoV 2 and other respiratory viruses.","authors":"André Emilio Viñán Garcés, Eder Cáceres, Juan Olivella Gómez, Ignacio Martín-Loeches, Luis Felipe Reyes","doi":"10.1080/14787210.2024.2400548","DOIUrl":"https://doi.org/10.1080/14787210.2024.2400548","url":null,"abstract":"Introduction: Lower respiratory tract infections (LRTI) remain a significant global cause of mortality and disability. Viruses constitute a substantial proportion of LRTI cases, with their pandemic potential posing a latent threat. After the SARS-CoV-2 pandemic, the resurgence of other respiratory viruses, including Influenza and Respiratory Syncytial Virus responsible for LRTI has been observed especially in susceptible populations.Areas covered: This review details the inflammatory mechanisms associated with three primary respiratory viruses: SARS-CoV-2, Influenza, and Respiratory Syncytial Virus (RSV). The focus will be on elucidating the activation of inflammatory pathways, understanding cellular contributions to inflammation, exploring the role of interferon and induced cell death in the response to these pathogens and detailing viral evasion mechanisms. Furthermore, the distinctive characteristics of each virus will be explained.Expert opinion: The study of viral pneumonia, notably concerning SARS-CoV-2, Influenza, and RSV, offers critical insights into infectious and inflammatory mechanisms with wide-ranging implications. Addressing current limitations, such as diagnostic accuracy and understanding host-virus interactions, requires collaborative efforts and investment in technology. Future research holds promise for uncovering novel therapeutic targets, exploring host microbiome roles, and addressing long-term sequelae. Integrating advances in molecular biology and technology will shape the evolving landscape of viral pneumonia research, potentially enhancing global public health outcomes.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges. 解码结核分枝杆菌复合体的耐药性：基因见解与未来挑战。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-04 DOI: 10.1080/14787210.2024.2400536

Amey Deshpande, Rupali Likhar, Tabassum Khan, Abdelwahab Omri

{"title":"Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges.","authors":"Amey Deshpande, Rupali Likhar, Tabassum Khan, Abdelwahab Omri","doi":"10.1080/14787210.2024.2400536","DOIUrl":"10.1080/14787210.2024.2400536","url":null,"abstract":"Introduction: Tuberculosis (TB), particularly its drug-resistant forms (MDR-TB and XDR-TB), continues to pose a significant global health challenge. Despite advances in treatment and diagnosis, the evolving nature of drug resistance in Mycobacterium tuberculosis (MTB) complicates TB eradication efforts. This review delves into the complexities of anti-TB drug resistance, its mechanisms, and implications on healthcare strategies globally.Areas covered: We explore the genetic underpinnings of resistance to both first-line and second-line anti-TB drugs, highlighting the role of mutations in key genes. The discussion extends to advanced diagnostic techniques, such as Whole-Genome Sequencing (WGS), CRISPR-based diagnostics and their impact on identifying and managing drug-resistant TB. Additionally, we discuss artificial intelligence applications, current treatment strategies, challenges in managing MDR-TB and XDR-TB, and the global disparities in TB treatment and control, translating to different therapeutic outcomes and have the potential to revolutionize our understanding and management of drug-resistant tuberculosis.Expert opinion: The current landscape of anti-TB drug resistance demands an integrated approach combining advanced diagnostics, novel therapeutic strategies, and global collaborative efforts. Future research should focus on understanding polygenic resistance and developing personalized medicine approaches. Policymakers must prioritize equitable access to diagnosis and treatment, enhancing TB control strategies, and support ongoing research and augmented government funding to address this critical public health issue effectively.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current understanding of infection of the ventricles and its complications. 目前对脑室感染及其并发症的认识。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-30 DOI: 10.1080/14787210.2024.2395018

Hazim Allos, Rodrigo Hasbun

{"title":"Current understanding of infection of the ventricles and its complications.","authors":"Hazim Allos, Rodrigo Hasbun","doi":"10.1080/14787210.2024.2395018","DOIUrl":"10.1080/14787210.2024.2395018","url":null,"abstract":"Introduction: Ventriculitis, characterized by inflammation of the ventricles in the brain, frequently occurs as a complication of neurosurgical interventions such as the insertion of cerebrospinal fluid (CSF) shunts or external ventricular drains. It can also present as a community-acquired pathology, broadening its clinical significance and complicating diagnosis and treatment. This condition presents significant challenges, primarily due to its association with various medical devices and the predisposing conditions of patients which enhance infection risks.Areas covered: The review comprehensively explores the etiology, risk factors, diagnostic methodologies, and treatment options for ventriculitis. A thorough literature search was conducted, focusing on recent studies, meta-analyses, and clinical reports that discuss the incidence rates, the effectiveness of different management strategies, and the impact of device-related and community-acquired infections. Particular attention is given to the role of CSF drains and shunts, biofilms, and the prophylactic measures employed in clinical settings to mitigate infection risks.Expert opinion: Despite advances in medical technology and infection control protocols, ventriculitis remains a severe complication in both neurosurgical and community settings. The review highlights the need for continued research into innovative diagnostic tools and more effective infection control strategies.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection. 揭示微/纳米生物材料在治疗幽门螺旋杆菌感染中的潜在作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-29 DOI: 10.1080/14787210.2024.2391910

Misagh Fathi Kisomi, Abbas Yadegar, Tara Shekari, Mohsen Amin, Antoni Llopis-Lorente, Chenguang Liu, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Mohammad Ali Shokrgozar, Mohammad Reza Zali, Mazda Rad-Malekshahi, Amir Hossein Miri, Michael R Hamblin, Matthias G Wacker

{"title":"Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection.","authors":"Misagh Fathi Kisomi, Abbas Yadegar, Tara Shekari, Mohsen Amin, Antoni Llopis-Lorente, Chenguang Liu, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Mohammad Ali Shokrgozar, Mohammad Reza Zali, Mazda Rad-Malekshahi, Amir Hossein Miri, Michael R Hamblin, Matthias G Wacker","doi":"10.1080/14787210.2024.2391910","DOIUrl":"https://doi.org/10.1080/14787210.2024.2391910","url":null,"abstract":"Introduction: Helicobacter pylori causes stubborn infections and leads to a variety of stomach disorders, such as peptic ulcer, chronic atrophic gastritis, and gastric cancer. Although antibiotic-based approaches have been widely used against H. pylori, some challenges such as antibiotic resistance are increasing in severity. Therefore, simpler but more effective strategies are needed.Areas covered: In this review, basic information on functionalized and non-functionalized micro/nano biomaterials and routes of administration for H. pylori inhibition are provided in an easy-to-understand format. Afterward, in vitro and in vivo studies of some promising bio-platforms including metal-based biomaterials, biopolymers, small-molecule saccharides, and vaccines for H. pylori inhibition are discussed in a holistic manner.Expert opinion: Functionalized or non-functionalized micro/nano biomaterials loaded with anti-H. pylori agents can show efficient bactericidal activity with no/slight negative influence on the host gastrointestinal microbiota. However, this claim needs to be substantiated with hard data such as assessment of the biopharmaceutical parameters of anti-H. pylori systems and the measurement of diversity/abundance of bacterial genera in the host gastric/gut microbiota before and after H. pylori eradication.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0